Long-term safety of QCZ484 in people with high blood pressure
Continues testing QCZ484 in adults with hypertension who finished an earlier study.
Plain-language title generated from the registry record
Registry title: An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.
Key facts
- Where
- Singapore, SingaporeSee the site
- Phase
- Phase 2
Where in Singapore
- SingaporeSingapore, SingaporeTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT07543120
- Record updated
- 30 July 2026
- Original description
The purpose of this extension study is to collect additional safety and efficacy on QCZ484 for hypertensive patients who successfully completed the parent study, CQCZ484A12201 or additional QCZ484 studies as specified in the respective parent study protocols.Read full original descriptionShow less
A Multicenter Open-label Extension Study to Evaluate Long-term Safety and Efficacy of QCZ484 in Hypertensive Patients.
The purpose of this extension study is to collect additional safety and efficacy on QCZ484 for hypertensive patients who successfully completed the parent study, CQCZ484A12201 or additional QCZ484 studies as specified in the respective parent study protocols.
Inclusion: Signed informed consent must be obtained prior to participation in the study; Successful completion of treatment period on QCZ484 study medication in parent study; No significant safety issue that may place participant at safety risk as determined by the Investigator.
Exclusion: Acute myocardial infarction (AMI) or unstable angina, or any percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) developed during the parent study. Any history of ischemic or hemorrhagic stroke or transient ischemic attack any time prior to enrollment; Other protocol-defined inclusion/exclusion criteria may apply; Evidence of hepatic disease that would put participant at risk by taking QCZ484 for long term as determined by the Investigator; Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), high-grade atrioventricular (AV) block (e.g., Mobitz type II and third-degree AV block in absence of a pacemaker) developed during the parent study; Clinically significant valvular heart disease developed during the parent study; Participants meeting any of the following criteria, may it be pre-existing or developed during the parent study, are not eligible for inclusion in this study:; Permanent or persistent atrial fibrillation developed during the parent study.